<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism - Andras, A - 2017 | Cochrane Library</title> <meta content="Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism - Andras, A - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002001.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism - Andras, A - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002001.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002001.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism" name="citation_title"/> <meta content="Alina Andras" name="citation_author"/> <meta content="Keele University" name="citation_author_institution"/> <meta content="alinaro@hotmail.com" name="citation_author_email"/> <meta content="Adriano Sala Tenna" name="citation_author"/> <meta content="Freeman Hospital" name="citation_author_institution"/> <meta content="Marlene Stewart" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD002001.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002001.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002001.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002001.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects, *therapeutic use]; Hemorrhage [chemically induced, epidemiology]; Heparin, Low‐Molecular‐Weight [adverse effects, *therapeutic use]; Incidence; Odds Ratio; Randomized Controlled Trials as Topic; Recurrence; Venous Thromboembolism [*drug therapy, mortality]; Venous Thrombosis [drug therapy]; Vitamin K [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002001.pub3&amp;doi=10.1002/14651858.CD002001.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002001\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002001\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002001.pub3",title:"Vitamin K antagonists versus low\\u2010molecular\\u2010weight heparin for the long term treatment of symptomatic venous thromboembolism",firstPublishedDate:"Jul 24, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002001.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002001.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002001.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002001.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002001.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002001.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002001.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002001.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002001.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002001.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2313 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002001.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/appendices#CD002001-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/table_n/CD002001StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/table_n/CD002001StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information#CD002001-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Alina Andras</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information#CD002001-cr-0003">Adriano Sala Tenna</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information#CD002001-cr-0004">Marlene Stewart</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information/en#CD002001-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002001.pub3">https://doi.org/10.1002/14651858.CD002001.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002001-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002001-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002001-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002001-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002001-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002001-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002001-abs-0001" lang="en"> <section id="CD002001-sec-0001"> <h3 class="title" id="CD002001-sec-0001">Background</h3> <p>People with venous thromboembolism (VTE) generally are treated for five days with intravenous unfractionated heparin or subcutaneous low‐molecular‐weight heparin (LMWH), followed by three months of vitamin K antagonists (VKAs). Treatment with VKAs requires regular laboratory measurements and carries risk of bleeding; some patients have contraindications to such treatment. Treatment with LMWH has been proposed to minimise the risk of bleeding complications. This is the second update of a review first published in 2001. </p> </section> <section id="CD002001-sec-0002"> <h3 class="title" id="CD002001-sec-0002">Objectives</h3> <p>The purpose of this review was to evaluate the efficacy and safety of long term treatment (three months) with LMWH versus long term treatment (three months) with VKAs for symptomatic VTE. </p> </section> <section id="CD002001-sec-0003"> <h3 class="title" id="CD002001-sec-0003">Search methods</h3> <p>For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (last searched November 2016) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10), The Cochrane Vascular Information Specialistalso searched clinical trials registries for ongoing studies. </p> </section> <section id="CD002001-sec-0004"> <h3 class="title" id="CD002001-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing LMWH versus VKA for long treatment (three months) of symptomatic VTE. Two review authors independently evaluated trials for inclusion and methodological quality. </p> </section> <section id="CD002001-sec-0005"> <h3 class="title" id="CD002001-sec-0005">Data collection and analysis</h3> <p>Review authors independently extracted data and assessed risk of bias. We resolved disagreements by discussion and performed meta‐analysis using fixed‐effect models with Peto odds ratios (Peto ORs) and 95% confidence intervals (CIs). Outcomes of interest were recurrent VTE, major bleeding, and mortality. We used GRADE to assess the overall quality of evidence supporting these outcomes. </p> </section> <section id="CD002001-sec-0006"> <h3 class="title" id="CD002001-sec-0006">Main results</h3> <p>Sixteen trials, with a combined total of 3299 participants fulfilled our inclusion criteria. According to GRADE, the quality of evidence was moderate for recurrent VTE, low for major bleeding, and moderate for mortality. We downgraded the quality of the evidence for imprecision (recurrent VTE, mortality) and for risk of bias and inconsistency (major bleeding). </p> <p>We found no clear differences in recurrent VTE between LMWH and VKA (Peto OR 0.83, 95% confidence interval (CI) 0.60 to 1.15; P = 0.27; 3299 participants; 16 studies; moderate‐quality evidence). We found less bleeding with LMWH than with VKA (Peto OR 0.51, 95% CI 0.32 to 0.80; P = 0.004; 3299 participants; 16 studies; low‐quality evidence). However, when comparing only high‐quality studies for bleeding, we observed no clear differences between LMWH and VKA (Peto OR 0.62, 95% CI 0.36 to 1.07; P = 0.08; 1872 participants; seven studies). We found no clear differences between LMWH and VKA in terms of mortality (Peto OR 1.08, 95% CI 0.75 to 1.56; P = 0.68; 3299 participants; 16 studies; moderate‐quality evidence). </p> </section> <section id="CD002001-sec-0007"> <h3 class="title" id="CD002001-sec-0007">Authors' conclusions</h3> <p>Moderate‐quality evidence shows no clear differences between LMWH and VKA in preventing symptomatic VTE and death after an episode of symptomatic DVT. Low‐quality evidence suggests fewer cases of major bleeding with LMWH than with VKA. However, comparison of only high‐quality studies for bleeding shows no clear differences between LMWH and VKA. LMWH may represent an alternative for some patients, for example, those residing in geographically inaccessible areas, those who are unable or reluctant to visit the thrombosis service regularly, and those with contraindications to VKA. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002001-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002001-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002001-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002001-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002001-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002001-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002001-abs-0006">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002001-abs-0005" lang="en"> <h3>Vitamin K antagonists or low‐molecular‐weight heparin for long term treatment of symptomatic blood clots </h3> <p><b>Background</b> </p> <p>Blood clots (venous thromboembolism) sometimes cause blockages in veins after surgery, during bed rest, or spontaneously. These clots can be fatal when they travel to the lungs. Vitamin K antagonists (VKAs), 99% of which consist of warfarin, are effective in preventing renewed blood clot formation, because they thin the blood. Low‐molecular‐weight heparins (LMWHs) are drugs that thin the blood and are used for people who are at risk of major bleeding, people who cannot take vitamin K antagonists, and pregnant women. </p> <p><b>Purpose of the review</b> </p> <p>To assess the benefits and harms of long term treatment (three months) of venous thromboembolism with LMWH compared with long term treatment with VKAs. </p> <p><b>Key results</b> </p> <p>This systematic review of 16 trials with a combined total of 3299 participants (current until November 2016) found no clear differences in recurrent blood clots and deaths between LMWH and VKA, and fewer bleeding episodes with LMWH than with VKA. However, comparison of only high‐quality studies for bleeding revealed no clear differences between LMWH and VKA. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence for the outcomes recurrent blood clots and death was moderate. The quality of this evidence was downgraded because of the small number of events reported, leading to imprecision. For the outcome bleeding, the quality of evidence was low because of inconsistency between studies and risk of bias. Continued research into long term treatment of blood clots in the veins with LMWH and VKA is needed. </p> <p><b>Authors' conclusions</b> </p> <p>This review found no clear differences in recurrent blood clots and death between LMWH and VKA, and fewer bleeding episodes with LMWH than with VKA. However, when only high‐quality studies were compared for bleeding, no clear differences were observed between LMWH and VKA. LMWH may offer an alternative for some patients, for example, those in geographically inaccessible areas, those unable or reluctant to visit the thrombosis service regularly, and those for whom taking VKA may be harmful. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002001-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002001-sec-0084"></div> <h3 class="title" id="CD002001-sec-0085">Implications for practice</h3> <section id="CD002001-sec-0085"> <p>Moderate‐quality evidence shows no clear differences between LMWH and VKA in preventing symptomatic VTE and mortality after an episode of symptomatic DVT. Low‐quality evidence suggests fewer cases of major bleeding with LMWH than with VKA. However, when only high‐quality studies are compared for bleeding, no clear difference between LMWH and VKA is evident. LMWH may present an alternative for some patients, for example, those in geographically inaccessible areas, those who are reluctant or unable to visit the thrombosis service regularly, and those with contraindications to VKAs. Only limited data are available for patients with symptomatic PE. </p> </section> <h3 class="title" id="CD002001-sec-0086">Implications for research</h3> <section id="CD002001-sec-0086"> <p>For more definitive conclusions, additional adequately designed randomised controlled clinical trials are needed, especially in the field of symptomatic PE. These trials must include patients with contraindications for VKAs (e.g. pregnant women), patients who are unable or reluctant to go to the thrombosis service on a regular basis, and patients living in geographically inaccessible areas. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002001-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002001-sec-0029"></div> <div class="table" id="CD002001-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LMWH compared with VKA for long term treatment of symptomatic VTE</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>LMWH compared with VKA for long term treatment of symptomatic VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE<br/> <b>Setting:</b> hospital and outpatient<br/> <b>Intervention:</b> LMWH<br/> <b>Comparison:</b> VKA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with VKA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of recurrent VTE</b> </p> <p>(treatment duration 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 0.83<br/> (0.60 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3299<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/> (31 to 58) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of major bleeding</b> </p> <p>(treatment duration 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 0.51<br/> (0.32 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3299<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (10 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(treatment duration 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 1.08<br/> (0.75 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3299<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000<br/> (26 to 53) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* The basis for the <b>assumed risk</b> with VKA for 'Study population' was the average risk in the VKA group (i.e. total number of participants with events divided by total number of participants in the VKA group included in the meta‐analysis). <b>The risk in the LMWH group</b> (and its 95% confidence interval) is based on assumed risk in the VKA group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; LMWH: low‐molecular‐weight heparin; OR: odds ratio; VKA: vitamin K antagonist; VTE: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>High risk of bias due to no blinding but not downgraded, as analysis excluding studies deemed of low methodological quality confirms no clear differences between LMWH and VKA<br/> <sup>b</sup>Downgraded by one level owing to imprecision, small number of events, and relatively large confidence interval<br/> <sup>c</sup>Downgraded by one level for risk of bias, as sensitivity analysis based on category I trials (clearly concealed randomisation, double‐blind or blinded outcome assessment) shows no clear differences between VKA and LMWH. Bleeding outcomes are more susceptible to biased outcome reporting than outcomes such as VTE and mortality<br/> <sup>d</sup>Downgraded by one level for inconsistency: only two studies (studies of low methodological quality) reported less bleeding for LMWH, and the remainder showed no clear differences, with confidence intervals crossing the line of no effect </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002001-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002001-sec-0030"></div> <section id="CD002001-sec-0031"> <h3 class="title" id="CD002001-sec-0031">Description of the condition</h3> <p>Venous thromboembolism (VTE) is defined as formation of thrombus in the deep veins, most commonly in the legs (deep vein thrombosis, or DVT), and/or subsequent embolisation of all or part of the thrombus to the pulmonary circulation (pulmonary embolisation, or PE). DVT of the lower limbs may be associated with localised pain, swelling, and erythema, as well as with development of pulmonary emboli (PE) and later occurrence of post‐thrombotic syndrome (PTS; persistent swelling, erythema, and ulceration). PE presents acutely with shortness of breath, pain on inspiration, tachycardia, and right heart overload, and, if untreated, can lead to circulatory collapse and death; over the longer term, PE can cause chronic post‐thrombotic pulmonary hypertension. In this era of more liberal central venous catheterisation, DVT may more often involve the upper extremities. Rarely, other venous circulation (within cerebral veins, portal and mesenteric veins, etc.) can be affected. </p> <p>In addition to DVT and PE, thrombus can form in the superficial veins, where it is associated with local pain and inflammation (superficial venous thrombosis). This event tends to be associated with lower rates of mortality and morbidity than are seen with DVT, although some patients may be at higher risk of DVT formation depending on the location of the clot (<a href="./references#CD002001-bbs2-0025" title="ChengelisDL , BendickPJ , GloverJL , BrownOW , RanvalTJ . Progression of superficial venous thrombosis to deep vein thrombosis. Journal of Vascular Surgery1996;24(5):745‐9. ">Chengelis 1996</a>; <a href="./references#CD002001-bbs2-0052" title="NasrH , ScrivenJM . Superficial thrombophlebitis (superficial venous thrombosis). BMJ2015;350:h2039. ">Nasr 2015</a>). </p> <p>Venous thromboembolism (VTE) comprises DVT and PE and can occur spontaneously. However, risk factors for VTE are many and include periods of inactivity, dehydration, hospitalisation, trauma, clotting disorders and previous thrombosis, varicose veins with phlebitis, pregnancy, use of oral combined hormonal contraceptives, malignancy, obesity, smoking, and advanced age (<a href="./references#CD002001-bbs2-0022" title="AndersonFA , SpencerFA . Risk factors for venous thromboembolism. Circulation2003;107(23 Suppl 1):I‐9. ">Anderson 2003</a>; <a href="./references#CD002001-bbs2-0053" title="National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods, evidence and guidance. http://www.nice.org.uk/guidance/cg92/evidence/cg92‐venous‐thromboembolism‐reducing‐the‐risk‐full‐guideline3 (accessed September 2015). ">NICE 2010</a>). </p> <p>The incidence of VTE in mostly Caucasian populations is between 100 and 200 per 100,000 person‐years (<a href="./references#CD002001-bbs2-0030" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12:464–74. [DOI: 10.1038/nrcardio.2015.83.] ">Heit 2015</a>; <a href="./references#CD002001-bbs2-0059" title="WhiteRH . The epidemiology of venous thromboembolism. Circulation2003;107:I‐4–I‐8. ">White 2003</a>). Of these, it is estimated that 45 to 117 per 100,000 person‐years are due to DVT (without PE) and 29 to 78 per 100,000 person‐years to PE (with or without DVT) (<a href="./references#CD002001-bbs2-0030" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12:464–74. [DOI: 10.1038/nrcardio.2015.83.] ">Heit 2015</a>). Recurrent VTE occurs in approximately 7.4% of patients at one year and in 30.4% of patients by 10 years (<a href="./references#CD002001-bbs2-0027" title="CushmanM . Epidemiology and risk factors for venous thrombosis. Seminars in Hematology2007;44(2):62‐9. ">Cushman 2007</a>; <a href="./references#CD002001-bbs2-0030" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12:464–74. [DOI: 10.1038/nrcardio.2015.83.] ">Heit 2015</a>; <a href="./references#CD002001-bbs2-0059" title="WhiteRH . The epidemiology of venous thromboembolism. Circulation2003;107:I‐4–I‐8. ">White 2003</a>). </p> </section> <section id="CD002001-sec-0032"> <h3 class="title" id="CD002001-sec-0032">Description of the intervention</h3> <p>The primary aim of treatment of symptomatic VTE is prevention of its recurrence, including prevention of potentially fatal PE. Clinical guidelines provide recommendations for treatment of VTE in different settings (<a href="./references#CD002001-bbs2-0044" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest2016;149(2):315‐52. ">Kearon 2016</a>; <a href="./references#CD002001-bbs2-0054" title="National Clinical Guideline Centre. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical Guideline. Methods, evidence and recommendations. http://www.nice.org.uk/guidance/cg144/evidence/cg144‐venous‐thromboembolic‐diseases‐full‐guideline3 (accessed September 2015). ">NICE 2012</a>). In general, anticoagulation is the recommended treatment of choice. The recommended initial treatment consists of a direct oral anticoagulant (with or without initial parenteral anticoagulation as indicated) or a parenteral anticoagulant given in conjunction with a VKA. Long term therapy (usually for a minimum duration of three months of anticoagulation) is indicated for treatment of acute VTE. </p> <p>Prolonged use of a VKA has proven efficacy in comparison with placebo and low‐dose heparin (unfractionated heparin) for treatment of VTE (<a href="./references#CD002001-bbs2-0035" title="HullR , DelmoreT , GentonE , HirschJ , GentM , SackettD , et al. Warfarin sodium versus low‐dose heparin in the long‐term treatment of venous thrombosis. The New England Journal of Medicine1979;301(16):855‐8. ">Hull 1979</a>; <a href="./references#CD002001-bbs2-0047" title="LagerstedtCI , OlssonCG , FagherBO , OqvistBW , AlbrechtssonU . Need for long‐term anticoagulant treatment in symptomatic calf‐vein thrombosis. Lancet1985;2(8454):515‐8. ">Lagerstedt 1985</a>). Use of adjusted therapeutic doses of subcutaneous unfractionated heparin is as effective as use of a VKA for preventing recurrence of symptomatic VTE, but both require regular laboratory monitoring (<a href="./references#CD002001-bbs2-0037" title="HullR , HirshJ , JayR , CarterC , EnglandC , GentM , et al. Different intensities of oral anticoagulant therapy in the treatment of proximal‐vein thrombosis. The New England Journal of Medicine1982;307(27):1676‐81. ">Hull 1982b</a>). Usual practice is to administer VKAs to achieve an international normalised ratio (INR) of 2.0 to 3.0 (<a href="./references#CD002001-bbs2-0036" title="HullR , DelmoreT , CarterC , HirshJ , GentonE , GentM , et al. Adjusted subcutaneous heparin versus warfarin sodium in the long‐term treatment of venous thrombosis. The New England Journal of Medicine1982;306(4):189‐94. ">Hull 1982a</a>). However, use of VKAs continues to present considerable risk of major bleeding (approximately 3% to 4%) during the first three months of treatment (<a href="./references#CD002001-bbs2-0042" title="HuttenBA , LensingAW , KraaijenhagenRA , PrinsMH . Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs and Aging1999;14(4):303‐12. ">Hutten 1999</a>). Moreover, for some patients, it is difficult to achieve a stable INR in the therapeutic range, and this leads to increased risk of bleeding complications. </p> </section> <section id="CD002001-sec-0033"> <h3 class="title" id="CD002001-sec-0033">How the intervention might work</h3> <p>Long term treatment of symptomatic VTE with low‐molecular‐weight heparin (LMWH) has been proposed to minimise risk of bleeding complications. Comparison of LMWH versus unfractionated heparin for initial treatment of symptomatic VTE reveals that LMWH is associated with a reduction in major bleeding (<a href="./references#CD002001-bbs2-0031" title="HettiarachchiRJK , PrinsMH , LensingAWA , BüllerHR . Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Current Opinion in Pulmonary Medicine1998;4:220‐5. ">Hettiarachchi 1998</a>), and that treatment with LMWH is less frequently complicated by thrombocytopaenia (<a href="./references#CD002001-bbs2-0058" title="WarkentinTE , LevineMN , HirshJ , HorsewoodP , RobertsRS , GentM , et al. Heparin‐induced thrombocytopenia in patients treated with low‐molecular‐weight heparin or unfractionated heparin. The New England Journal of Medicine1995;332(20):1330‐6. ">Warkentin 1995</a>) and osteoporosis (<a href="./references#CD002001-bbs2-0045" title="KeltonJG , WarkentinTE . Diagnosis of heparin‐induced thrombocytopenia. Still a journey, not yet a destination. American Journal of Clinical Pathology1995;104(6):611‐3. ">Kelton 1995</a>; <a href="./references#CD002001-bbs2-0051" title="MonrealM , LafozE , OliveA , delRioL , VediaC . Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis1994;71(1):7‐11. ">Monreal 1994</a>); also, these compounds do not require laboratory monitoring. </p> </section> <section id="CD002001-sec-0034"> <h3 class="title" id="CD002001-sec-0034">Why it is important to do this review</h3> <p>If the efficacy and safety of LMWH are found to be comparable with those of VKAs, LMWH could be used for long term treatment of symptomatic VTE. This would be especially important for patients in whom VKAs are contraindicated or impractical, for example, pregnant women and those living in geographically inaccessible places. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002001-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002001-sec-0035"></div> <p>The purpose of this review was to evaluate the efficacy and safety of long term treatment (three months) with LMWH versus long term treatment (three months) with VKAs for symptomatic VTE. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002001-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002001-sec-0036"></div> <section id="CD002001-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002001-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included trials that randomly allocated participants to long term (three months) treatment with VKAs or LMWH. </p> </section> <section id="CD002001-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included trials involving participants with symptomatic venous thromboembolism (VTE). We excluded trials that exclusively included participants with active malignancy and symptomatic VTE because this is the topic of another Cochrane review (<a href="./references#CD002001-bbs2-0021" title="AklEA , KahaleLA , BarbaM , NeumannI , LabediN , TerrenatoI , et al. Anticoagulation for the long‐term treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD006650.pub4] ">Akl 2014</a>). In addition, we excluded trials when investigators did not use objective tests to confirm the diagnosis of deep venous thrombosis (DVT) (such as venography, ultrasound, or any sequence of tests that results in a high positive predictive value for the diagnosis of symptomatic DVT) or the diagnosis of pulmonary embolism (PE) (such as high‐probability ventilation‐perfusion lung scan or pulmonary angiography). </p> </section> <section id="CD002001-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing VKAs versus LMWH for long term (three months) treatment of symptomatic VTE. Trials were included if the initial treatment for symptomatic VTE consisted of LMWH or unfractionated heparin for 5 to 10 days. </p> </section> <section id="CD002001-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD002001-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002001-list-0001"> <li> <p>Incidence of recurrent symptomatic VTE during three months of allocated treatment</p> </li> <li> <p>Occurrence of major bleeding complications during three months of allocated treatment</p> </li> <li> <p>Mortality during three months of allocated treatment</p> </li> </ul> </p> <p>To confirm an episode of suspected recurrent VTE, we considered the following criteria as constituting a positive diagnosis of recurrent symptomatic DVT. </p> <p> <ul id="CD002001-list-0002"> <li> <p>Extension of an intraluminal filling defect on a venogram.</p> </li> <li> <p>New intraluminal filling defect.</p> </li> <li> <p>Extension of non‐visualisation of proximal veins in the presence of a sudden cut‐off defect on a venogram seen on at least two projections. </p> </li> </ul> </p> <p>When no previous venogram was available for comparison, we considered an intraluminal filling defect as sufficient. When no venogram was available, we accepted abnormal results of compression ultrasonography in an area where compression had previously been normal, or a substantial increase in the diameter of the thrombus during full compression at the popliteal or femoral vein (<a href="./references#CD002001-bbs2-0046" title="KoopmanMM , PrandoniP , PiovellaP , OckelfordPA , BrandjesDP , van derMeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low‐molecular‐weight heparin administered at home. The Tasman Study Group. The New England Journal of Medicine1996;334(11):682‐7. ">Koopman 1996</a>; <a href="./references#CD002001-bbs2-0048" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low‐molecular‐weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep‐vein thrombosis. The New England Journal of Medicine1996;334(11):677‐81. ">Levine 1996</a>). When neither a venogram nor an ultrasonographic trial was available, a change in the results of impedance plethysmography from normal to abnormal, accompanied by a change from a negative to a positive result on a D‐dimer test, was acceptable. </p> <p>To confirm an episode of suspected recurrent PE, we accepted the following criteria.</p> <p> <ul id="CD002001-list-0003"> <li> <p>New intraluminal filling defect.</p> </li> <li> <p>Extension of an existing defect.</p> </li> <li> <p>Sudden cut‐off of vessels &gt; 2.5 mm in diameter on a pulmonary angiogram.</p> </li> </ul> </p> <p>When no prior pulmonary angiogram was available, an intraluminal filling defect or a sudden cut‐off of vessels &gt; 2.5 mm in diameter on a pulmonary angiogram was sufficient. When no pulmonary angiogram was available, we accepted a defect of ≥ 75% of a segment on the perfusion scan with normal ventilation. When the ventilation‐perfusion scan was non‐diagnostic (and no pulmonary angiogram was available), satisfaction of the above criteria for DVT was acceptable. Pulmonary embolism demonstrated at autopsy was also acceptable. </p> <p>We classified haemorrhages as major if they were clinically overt and associated with a fall in haemoglobin level ≥ 2 g/dL (1.6 mM); clinically overt and leading to transfusion of ≥ 2 units of packed cells; intracranial; retroperitoneal; leading directly to death; or leading to interruption of antithrombotic treatment or (re)operation. </p> <p>We excluded studies that evaluated bleeding if definitions of major and minor bleeding were unclear. </p> </section> <section id="CD002001-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002001-list-0004"> <li> <p>Incidence of recurrent symptomatic VTE during additional six to nine months after cessation of allocated three months of treatment for symptomatic VTE </p> </li> <li> <p>Occurrence of major bleeding complications during additional six to nine months after cessation of allocated three months of treatment for symptomatic VTE </p> </li> <li> <p>Mortality during additional six to nine months after cessation of allocated three months of treatment for symptomatic VTE </p> </li> </ul> </p> <p>We considered additional long term outcomes for inclusion in the review when these were available. </p> </section> </section> </section> <section id="CD002001-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We applied no language restrictions on publications and no restrictions regarding status of publications. </p> <section id="CD002001-sec-0045"> <h4 class="title">Electronic searches</h4> <p>For this update, the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials. </p> <p> <ul id="CD002001-list-0005"> <li> <p>Cochrane Vascular Specialised Register (11 November 2016).</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10) via the Cochrane Register of Studies Online. </p> </li> </ul> </p> <p>See <a href="./appendices#CD002001-sec-0090">Appendix 1</a> for details of the search strategy used to search CENTRAL. </p> <p>The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Allied and Complementary Medicine Database (AMED), and through handsearching of relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Vascular module in The Cochrane Library (<a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>). </p> <p>The CIS searched the following trial registries for details of ongoing and unpublished studies (11 November 2016). </p> <p> <ul id="CD002001-list-0006"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/trialsearch</a>). </p> </li> <li> <p>ISRCTN Register (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> </li> </ul> </p> <p>See <a href="./appendices#CD002001-sec-0091">Appendix 2</a>. </p> </section> <section id="CD002001-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of articles retrieved by electronic searches for additional citations. We contacted trialists for further information when data were missing, or when we had doubts about whether we should include specific trials in the review. </p> </section> </section> <section id="CD002001-sec-0047"> <h3 class="title" id="CD002001-sec-0047">Data collection and analysis</h3> <section id="CD002001-sec-0048"> <h4 class="title">Selection of studies</h4> <p>At least two members of the current review author team (AA, AST, MS) independently scrutinised trials for eligibility and resolved disagreements by discussion. We obtained full versions of articles that potentially met our inclusion criteria upon review of titles or abstracts and assessed these trials independently against the inclusion criteria. We have presented the reason for exclusion of each study in the <a href="./references#CD002001-sec-0107" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD002001-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We reviewed eligible articles and extracted and recorded summary information on forms developed by Cochrane Vascular. We sought the following information: participant characteristics (age, gender, comorbidities); number of participants in each treatment arm; duration of therapy; type of anticoagulant (vitamin K antagonist/LMWH); and incidence and timing of recurrent VTE, major bleeding complications, and mortality. When important information was not reported, we contacted trial authors. </p> </section> <section id="CD002001-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors working independently (AA, MS) used the 'Risk of bias tool' as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002001-bbs2-0032" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) to assess sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias, judging each item to be at low, unclear, or high risk of bias according to guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> <p>We then classified trials into two categories. Category I trials were those with high methodological quality, that is, clearly concealed randomisation and double‐blind treatment or blinded assessment of outcome measures. Category II trials were those with lower methodological quality, that is, unclear or clearly not concealed randomisation or blind outcome assessment. We sought all information regarding adequacy of the randomisation process, allocation concealment, blinding, intention‐to‐treat analysis, and completeness of follow‐up. </p> </section> <section id="CD002001-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5.3 as provided by Cochrane to analyse data. For dichotomous outcomes, we have presented results of statistical analysis as Peto odds ratios (Peto ORs) with 95% confidence intervals (CIs). </p> </section> <section id="CD002001-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>Participating individuals were the unit of analysis.</p> </section> <section id="CD002001-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>When necessary, we contacted the authors of included trials to clarify data and provide missing values. </p> </section> <section id="CD002001-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We conducted all analyses on an intention‐to‐treat basis. When individual trials did not use intention‐to‐treat analysis, we analysed data (absolute numbers) as provided in the included trial report. </p> <p>We assessed trial heterogeneity using the I<sup>2</sup> statistic, which describes the percentage of variability in effect estimates that is due to heterogeneity rather than to sampling error (chance). When we identified heterogeneity (I<sup>2</sup> &gt; 50%), we investigated reasons for this. </p> </section> <section id="CD002001-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We used asymmetry in funnel plots to assess reporting bias when we included more than 10 studies in the meta‐analysis (<a href="./references#CD002001-bbs2-0032" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD002001-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We combined calculated Peto ORs from individual trials across trials, giving weight to the number of events reported in each of the two treatment groups for each separate trial. This approach assumes the use of a fixed‐effect analysis model (<a href="./references#CD002001-bbs2-0026" title="CollinsR , GrayR , GodwinJ , PetoR . Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statistics in Medicine1987;6(3):245‐54. ">Collins 1987</a>; <a href="./references#CD002001-bbs2-0049" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719‐48. ">Mantel 1959</a>). </p> <p>We performed separate analyses for all trials combined and for trials of high methodological quality (Category I) (see <a href="#CD002001-sec-0050">Assessment of risk of bias in included studies</a>). </p> </section> <section id="CD002001-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed separate analyses for trials that used similar initial treatment in both trial arms and for those that used different treatment regimens during initial treatment for PE or DVT (i.e. LMWH vs unfractionated heparin for initial treatment of symptomatic VTE ‐ a potential source of confounding). In addition, we performed analyses for symptomatic PE and symptomatic DVT to explore the effects of vitamin K antagonists on these two different disease components of symptomatic VTE. </p> </section> <section id="CD002001-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>The primary analysis included data on all trial participants during the period of randomly allocated treatment. We performed sensitivity analyses to explore the effect that risk of bias had on estimates of treatment effects by excluding studies classified as category II trials (trials with low methodological quality, i.e. unclear or clearly not concealed randomisation or no blind outcome assessment; see <a href="#CD002001-sec-0050">Assessment of risk of bias in included studies</a>). </p> <section id="CD002001-sec-0059"> <h5 class="title">'Summary of findings'</h5> <p>We presented the main findings of this review regarding quality of evidence, magnitude of effects of interventions examined, and sum of available data on primary outcomes (<a href="#CD002001-sec-0041">Types of outcome measures</a>) in a 'Summary of findings' table, according to GRADE principles as described by <a href="./references#CD002001-bbs2-0032" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a> and <a href="./references#CD002001-bbs2-0023" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490‐4. ">Atkins 2004</a>. We developed a 'Summary of findings' table for the comparison 'LMWH versus VKA during allocated treatment (category I and II studies)' and used GRADEpro (GRADEproGDT) software (<a href="http://www.guidelinedevelopment.org/" target="_blank">http://www.guidelinedevelopment.org/</a>) to facilitate preparation of the 'Summary of findings' table. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002001-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002001-sec-0060"></div> <section id="CD002001-sec-0061"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD002001-sec-0106" title="">Characteristics of included studies</a> and <a href="./references#CD002001-sec-0107" title="">Characteristics of excluded studies</a>. </p> <section id="CD002001-sec-0062"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD002001-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD002001-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002001-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified one new study that was eligible for inclusion in this update (<a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>). </p> </section> <section id="CD002001-sec-0063"> <h4 class="title">Included studies</h4> <p>In total, 16 trials that examined long term treatment of symptomatic VTE fulfilled our inclusion criteria (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). Three trials (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>) included only participants with symptomatic PE. One trial included participants with both symptomatic DVT and symptomatic PE (<a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>). The 12 remaining trials included participants with symptomatic DVT. See the <a href="./references#CD002001-sec-0106" title="">Characteristics of included studies</a> table for a detailed description of these trials. </p> <p>The trials were performed in the following countries.</p> <p> <ul id="CD002001-list-0007"> <li> <p>Canada (<a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>). </p> </li> <li> <p>Germany (<a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>). </p> </li> <li> <p>Greece (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>). </p> </li> <li> <p>Italy (<a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>). </p> </li> <li> <p>Poland (<a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>). </p> </li> <li> <p>Spain (<a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). </p> </li> <li> <p>USA (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>). </p> </li> <li> <p>UK (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>). </p> </li> </ul> </p> <p>The 16 included trials recruited a total of 3299 participants. The number of participants in each trial ranged from 40 (<a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>) to 737 (<a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>). Seven trials provided similar treatments in both arms (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>); the remaining nine trials allocated participants to different treatments provided in different trial arms (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). The 16 included trials were published between 1994 and 2010 (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). </p> <p>Category I trials were those with high methodological quality, that is, clearly concealed randomisation and double‐blind treatment or blinded assessment of outcome measures. Category II trials were those with lower methodological quality, that is unclear or clearly not concealed randomisation or blind outcome assessment. We deemed that seven trials were category I trials (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) and the remaining nine trials were category II trials (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). For additional details on methodological quality, see the <a href="#CD002001-sec-0065">Risk of bias in included studies</a> section. </p> <p>Seven of the 16 trials included only participants with symptomatic DVT and used similar initial treatment in both treatment arms. These included two category I trials (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) and five category II trials (<a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). The category II trial <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a> randomised participants between three treatment arms; in one arm, initial treatment was intravenous unfractionated heparin followed by three months of VKA. The other two treatment arms initially treated participants with LMWH followed by a VKA or LMWH for 12 weeks. In the category I trials <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>, <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>, and <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>, initial treatment in the LMWH arm consisted of subcutaneous LMWH, and initial treatment in the VKA arm consisted of a course of intravenous unfractionated heparin. Category I trial <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a> included only participants with acute proximal DVT; initial treatment consisted of subcutaneous LMWH or subcutaneous LMWH plus warfarin. Among trials including only participants with symptomatic PE (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>), <a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a> compared different initial treatments, but <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a> and <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a> provided the same initial treatment, that is, subcutaneous LMWH. One trial included participants with both symptomatic DVT and symptomatic PE (<a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>) and provided different initial treatment for the two treatment groups. </p> <p><a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a> followed all participants for the entire follow‐up period and performed intention‐to‐treat analysis. <a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a> reported that a total of 19 participants (18%) did not complete the trial according to the protocol; six participants in the LMWH group did not complete the three months of follow‐up (one death, one severe illness, two PE, one loss to follow‐up, one inadequate venogram); 13 participants in the VKA group did not complete the three months of follow‐up (three deaths, three severe illness, one PE, three losses to follow‐up, three inadequate venograms); and analyses of participant data were based on an intention‐to‐treat analysis. <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a> excluded 20 (11%) participants from the analysis: eight participants in the LMWH arm and 12 in the vitamin K antagonist arm. Investigators did not provide results of intention‐to‐treat analysis nor outcome data (in total, 12 participants had no second venogram, five participants received treatment that was not conducted properly, and three participants were lost to follow‐up). <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a> excluded a total of nine participants after randomisation and performed no intention‐to‐treat analyses. Three participants in the LMWH group (one sudden death during initial treatment, one PE (day three) and vena caval filter insertion (day 14), and one initial treatment changed to unfractionated heparin) and six in the VKA group (two with an exclusion criterion overlooked (vein compression by arterial aneurysm), three consent withdrawals, and one initial treatment changed to thrombectomy) did not complete the trial according to the protocol. <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a> reported that 54 participants were not included in the intention‐to‐treat analysis (evenly divided over the three treatment arms), six participants did not have a baseline venography, and in 48 participants symptomatic DVT was not confirmed independently by the baseline venogram. <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a> reported that a total of six participants were excluded before commencement of treatment (five in the LMWH arm and one in the VKA arm). <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a> reported that a total of six participants did not complete the trial according to the protocol and provided intention‐to‐treat analysis of data for these participants. In the VKA arm, four participants did not complete the trial (one was lost to follow‐up and three withdrew consent); and in the LMWH arm, two participants did not complete the trial (one was lost to follow‐up and one withdrew consent). <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a> reported that 3 of 480 participants were lost to follow‐up at 12 months (1 in the heparin group and 2 in the usual care group). <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a> reported that eight participants did not complete the study protocol successfully; five participants (9.7%) randomised to heparin (metastatic cancer, allergy to heparin, vein thrombosis, and two unknown reasons) and three (6%) to VKA (metastatic cancer, inability to reach therapeutic INR, and one unknown reason). <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>, <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>, <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>, <a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>, <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>, and <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a> reported that all trial participants were followed‐up. <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a> reported use of intention‐to‐treat analyses but excluded two participants ‐ one from each group, who did not receive study medications ‐ from these analyses. Two participants failed to meet inclusion criteria and two failed to meet exclusion criteria, but these participants did receive study medications and were left in the intention‐to‐treat analyses. <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a> reported that eight participants (including one death) in the LMWH group and 14 (including 4 deaths) in the unfractionated heparin group withdrew from the study. </p> <p>All included studies provided a minimum of three months of treatment. Three studies reported a treatment period of six months (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>), and in three other studies some participants received three months of treatment and others six months of treatment (<a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). A total of 12 studies reported additional follow‐up after cessation of treatment ranging from 28 days to 9 months (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). </p> <p>Seven trials described quality of treatment with VKAs, defined as INR between 2.0 and 3.0 (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>); percentages are given in the <a href="./references#CD002001-sec-0106" title="">Characteristics of included studies</a> table. <a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a> and <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a> provided INRs for participants who had a major bleeding complication. <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a> provided INRs for some of the participants with bleeding complications. </p> </section> <section id="CD002001-sec-0064"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded four studies. Reasons for exclusion included the following.</p> <p> <ul id="CD002001-list-0008"> <li> <p>Non‐randomised trial (<a href="./references#CD002001-bbs2-0020" title="VorobyevaNM , PanchenkoEP , KirienkoAI , DobrovolskyAB , TitaevaEV , ErmolinaOV , et al. Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment [Russian]. Therapeutic Archives2009;81(9):57‐61. ">Vorobyeva 2009</a>). </p> </li> <li> <p>Composite endpoint trial (<a href="./references#CD002001-bbs2-0017" title="GhirarduzziA , CamporeseG , SiragusaS , ImbertiD , BucheriniE , LandiniF , et al. A randomized, prospective, open‐label study on distal vein thrombosis (low‐molecular‐weight heparin vs. warfarin for 6 weeks): the Todi study. Journal of Thrombosis and Haemostasis2009;7 Suppl 2:Abstract: PP‐WE‐403. ">Ghirarduzzi 2009</a>). </p> </li> <li> <p>Subjective reporting (<a href="./references#CD002001-bbs2-0018" title="HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy out‐of‐hospital versus warfarin sodium comparing the post‐phlebitic outcomes at three months. Blood2001;98(11):Abstract 1873. ">Hull 2001</a>; <a href="./references#CD002001-bbs2-0019" title="HullRD , PineoGF , MahAF , BrantRF . Long‐term out‐of hospital treatment with low‐molecular‐weight heparin versus warfarin sodium: a randomised trial comparing the quality of life associated with these antithrombotic therapies. Blood2001;98(11):Abstract 1124. ">Hull 2001a</a>). </p> </li> </ul> </p> </section> </section> <section id="CD002001-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD002001-fig-0002">Figure 2</a> and <a href="#CD002001-fig-0003">Figure 3</a> for graphical presentations of risk of bias. Lack of detail was the main reason for the 'unclear' rating for most trials. </p> <div class="figure" id="CD002001-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD002001-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD002001-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD002001-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <section id="CD002001-sec-0066"> <h4 class="title">Allocation</h4> <p>Nine trials described the method used to generate the random allocation sequence in sufficient detail, indicating low risk of bias (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>). The randomisation method was unclear in seven trials (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). </p> <p>Only three trials adequately concealed allocation (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). We determined that the remaining 13 trials had unclear risk of bias (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>). </p> </section> <section id="CD002001-sec-0067"> <h4 class="title">Blinding</h4> <p>All included trials were at high risk of performance bias because they were open‐label trials. </p> <p>Eleven trials were at low risk of detection bias because they reported adequate blinding of outcome assessments (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). Two trials were at high risk of detection bias because they did not report blinded outcome assessment (<a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>); and three trials were at unclear risk of bias because it was unclear whether those collecting outcomes data were aware of the allocation (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>). </p> </section> <section id="CD002001-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of bias was low for 15 trials, as investigators followed‐up and reported on all participants (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). We classified only <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a> as having high risk of bias, as investigators did not follow up on 33% of randomised participants, as was required by the trial design. </p> </section> <section id="CD002001-sec-0069"> <h4 class="title">Selective reporting</h4> <p>Fourteen trials were at low risk of bias, and two trials (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>) had unclear risk of bias owing to insufficient information provided in trial reports. </p> </section> <section id="CD002001-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Nine trials were free of other sources of bias (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). However, one trial was at unclear risk, as investigators provided insufficient information (<a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>). We deemed <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a> to be at unclear risk of other bias because study authors did not discuss three fatal peripheral or cardiovascular events in the acenocoumarol group, and because follow‐up treatments after planned three‐month outcomes differed between groups. Five (category I) trials had unclear risk, as results may have been confounded by differences in the initial treatment (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>). </p> </section> </section> <section id="CD002001-sec-0071"> <h3 class="title" id="CD002001-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD002001-tbl-0001"><b>Summary of findings for the main comparison</b> LMWH compared with VKA for long term treatment of symptomatic VTE</a> </p> <section id="CD002001-sec-0072"> <h4 class="title">Incidence of recurrent venous thromboembolism during active treatment</h4> <p>All 16 trials reported the occurrence of recurrent symptomatic VTE during the first three months after randomisation. </p> <p>A total of 86 of 1702 participants (5.1%) in the VKA group had recurrent symptomatic VTE versus 70 of 1597 participants (4.4%) in the LMWH group. Pooled analysis showed no clear differences between treatment modalities for recurrent symptomatic VTE (Peto OR 0.83, 95% CI 0.60 to 1.15; P = 0.27; 3299 participants; 16 studies; moderate‐quality evidence) among participants with symptomatic VTE. Heterogeneity was assessed as I<sup>2</sup> = 9% (<a href="./references#CD002001-fig-0007" title="">Analysis 1.1</a>; <a href="#CD002001-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD002001-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.1 incidence of recurrent VTE." data-id="CD002001-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.1 incidence of recurrent VTE. </p> </div> </div> </div> <p>Although 15 trials showed no clear differences in recurrent VTE between LMWH and VKA treatment, one trial (<a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>) found a difference in favour of LMWH treatment (Peto OR 0.38, 95% CI 0.17 to 0.86; 185 participants). </p> <p>Twelve trials included only participants with symptomatic DVT. In these trials, a total of 82 of 1572 participants (5.2%) in the VKA group had recurrent symptomatic VTE versus 63 of 1449 participants (4.3%) in the LMWH group, showing no clear differences between treatment modalities for recurrent symptomatic VTE (Peto OR 0.79, 95% CI 0.57 to 1.11; P = 0.18; 3021 participants; 12 studies) among participants with symptomatic DVT. Heterogeneity was assessed as I<sup>2</sup> = 8% (<a href="./references#CD002001-fig-0010" title="">Analysis 2.1</a>). </p> <p>In contrast, among the three trials including only participants with symptomatic PE, none of 90 participants (0%) in the VKA group had recurrent symptomatic VTE versus 5 of 112 participants (4.5%) in the LMWH group, resulting in no clear differences between treatments for episodes of recurrent symptomatic VTE (Peto OR 5.70, 95% CI 0.91 to 35.60; P = 0.06; 202 participants; three studies) among participants with symptomatic PE. Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0013" title="">Analysis 3.1</a>). </p> <p>Consideration of category I trials (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) revealed that six trials included only participants with symptomatic DVT and the remaining trial (<a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>) included participants with both symptomatic DVT and PE. A total of 61 of 941 participants (6.5%) in the VKA arm had recurrent symptomatic VTE versus 49 of 931 participants (5.3%) allocated to LMWH treatment during three months of treatment. Analysis of pooled data showed no clear differences between treatment modalities for recurrent symptomatic VTE (Peto OR 0.80, 95% CI 0.54 to 1.18; P = 0.26; 1872 participants; seven studies). Heterogeneity was assessed as I<sup>2</sup> = 16% (<a href="./references#CD002001-fig-0016" title="">Analysis 4.1</a>). </p> <p>Five category I trials may have been confounded by differences in initial treatment (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>). Analysing these trials separately revealed no clear differences between treatment groups (Peto OR 0.68, 95% CI 0.44 to 1.03; P = 0.07; 1580 participants; five studies). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0022" title="">Analysis 6.1</a>). We considered in a separate analysis the two category I trials that compared a VKA versus LMWH for long term treatment of symptomatic VTE, using the same initial treatment in both arms (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>). Analysis of pooled data showed no clear differences in recurrent symptomatic VTE between treatments (Peto OR 1.95, 95% CI 0.74 to 5.19; P = 0.18; 292 participants; two studies). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0019" title="">Analysis 5.1</a>). </p> </section> <section id="CD002001-sec-0073"> <h4 class="title">Incidence of recurrent symptomatic venous thromboembolism during the additional period of follow‐up after cessation of active treatment </h4> <p>Five category I trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) and five category II trials (<a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>) evaluated a period of six to nine months after cessation of the allocated treatment. A total of 53 of 1296 participants (4.1%) in the VKA group versus 59 of 1296 participants (4.6%) in the arm allocated to LMWH treatment experienced an episode of recurrent symptomatic VTE. Combined analysis showed no clear differences in recurrent symptomatic VTE between treatment arms (Peto OR 1.12, 95% CI 0.77 to 1.64; P = 0.56; 2592 participants; 10 studies). Heterogeneity was assessed as I<sup>2</sup> = 28% (<a href="./references#CD002001-fig-0025" title="">Analysis 7.1</a>). </p> <p>A separate analysis for the category I trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) evaluating an additional period of nine months after cessation of the allocated treatment resulted in a total of 36 of 846 participants (4.3%) in the VKA arm versus 45 of 845 participants (5.3%) in the LMWH arm experiencing an episode of recurrent symptomatic VTE. Combined analysis showed no clear differences in thromboembolic complications between treatment modalities (Peto OR 1.26, 95% CI 0.81 to 1.98; P = 0.30; 1691 participants; five studies). Heterogeneity was assessed as I<sup>2</sup> = 14% (<a href="./references#CD002001-fig-0028" title="">Analysis 8.1</a>). It should be noted that in <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>, 34 of 94 participants used the VKA during an additional three months and 14 of 94 participants used the VKA for an additional nine months, whereas in the LMWH group all 93 participants stopped assigned treatment after three months. Furthermore, in <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>, 250 of 368 participants in the VKA allocated treatment arm were treated with LMWH beyond the three months of allocated treatment and in the LMWH group 146 of 369 participants continued allocated treatment beyond the three months of allocated treatment. <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a> reported that some participants in both treatment groups received ongoing warfarin after the first three months of allocated treatment. </p> <p>The total 12‐month period of follow‐up (combining three months of active treatment and nine months of follow‐up) among five category I trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) included a total of 91 of 846 participants (10.8%) in the VKA group versus 87 of 845 participants (10.3%) in the LMWH group who had recurrent symptomatic VTE and showed no clear differences between treatment modalities for risk of recurrent symptomatic VTE (Peto OR 0.95, 95% CI 0.70 to 1.30; P = 0.75; 1691 participants; five studies) among participants with symptomatic PE. Heterogeneity was assessed as I<sup>2</sup> = 58% (<a href="./references#CD002001-fig-0034" title="">Analysis 10.1</a>). </p> <p>Analysis of pooled data from 10 category I and category II trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>) showed no clear differences between LMWH and VKA treatment for the total 12‐month period of follow‐up (Peto OR 0.88, 95% CI 0.67 to 1.15; P = 0.34; 2592 participants; 10 studies). Heterogeneity was assessed as I<sup>2</sup> = 41% (<a href="./references#CD002001-fig-0031" title="">Analysis 9.1</a>). </p> </section> <section id="CD002001-sec-0074"> <h4 class="title">Incidence of major bleeding during active treatment</h4> <p>All 16 category I and II trials reported the incidence of major bleeding during allocated treatment. Thirteen trials found no clear differences and only two trials found differences between groups (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>). <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a> found a difference that favoured the LMWH group (Peto OR 0.12, 95% CI 0.02 to 0.89). This trial included only participants with DVT. <a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a> found a difference that favoured the LMWH group (Peto OR 0.05, 95% CI 0.00 to 0.92). This trial included only participants with symptomatic PE. </p> <p>Analysis of pooled trials showed major bleeding complications among 50 of 1702 participants (2.9%) in the VKA arm versus 25 of 1597 participants (1.6%) in the LMWH group. This difference favoured LMWH therapy for the outcome of major bleeding (Peto OR 0.51, 95% CI 0.32 to 0.80; P = 0.004; 3299 participants; 16 studies; low‐quality evidence). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0008" title="">Analysis 1.2</a>; <a href="#CD002001-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD002001-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.2 incidence of major bleeding." data-id="CD002001-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.2 incidence of major bleeding. </p> </div> </div> </div> <p>Analysing the 12 trials that included only participants with symptomatic DVT revealed that a total of 42 of 1572 participants (2.7%) in the VKA group had major bleeding versus 22 of 1449 participants (1.5%) in the LMWH group, showing a difference between treatment modalities that favoured LMWH for the outcome of major bleeding (Peto OR 0.54, 95% CI 0.33 to 0.88; P = 0.01; 3021 participants; 12 studies) among participants treated with symptomatic DVT. Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0011" title="">Analysis 2.2</a>). </p> <p>The three trials (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0013" title="Pérez‐de‐LlanoLA , Leiro‐FernándezV , GolpeR , Núñez‐DelgadoJM , Palacios‐BartoloméA , Méndez‐MaroteL , et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagulation &amp; Fibrinolysis2010;21(8):744‐9. ">Perez‐de‐Llano 2010</a>) that included only participants with symptomatic PE observed major bleeding in a total of 3 of 90 participants (3.3%) in the VKA group versus 1 of 112 participants (0.9%) in the LMWH group, revealing no clear differences between treatments for the outcome of major bleeding (Peto OR 0.23, 95% CI 0.03 to 1.78; P = 0.16; 202 participants; three studies) among participants treated for symptomatic PE. Heterogeneity was assessed as I<sup>2</sup> = 52% (<a href="./references#CD002001-fig-0014" title="">Analysis 3.2</a>). </p> <p>Consideration of only category I trials (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) revealed that a total of 34 of 941 participants (3.6%) in the VKA arm versus 21 of 931 participants (2.3%) allocated to LMWH treatment experienced major bleeding during three months of treatment. Analysis of pooled data showed no clear differences between treatment modalities for the outcome of major bleeding (Peto OR 0.62, 95% CI 0.36 to 1.07; P = 0.08; 1872 participants; seven studies). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0017" title="">Analysis 4.2</a>). </p> <p>We performed <i>post hoc</i> analyses to assess the subsets of participants with fatal haemorrhage and intracranial haemorrhage to determine how LMWH and VKA differ with respect to severe bleeds. We found no clear differences between LMWH and VKA among combined category I and category II studies and in category I studies only (results not shown). </p> <p>For two category I trials providing the same initial treatment in both groups (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) analysis of data showed no evidence of a difference in major bleeding incidence between treatment modalities (Peto OR 1.01, 95% CI 0.20 to 5.12; P = 0.99; 292 participants; two studies; I<sup>2</sup> = not applicable) (<a href="./references#CD002001-fig-0020" title="">Analysis 5.2</a>). For five category I trials providing different initial treatments in the two groups (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>) analysis of data showed no clear differences between treatment modalities (Peto OR 0.59, 95% CI 0.33 to 1.04; P = 0.07; 1580 participants; five studies; I<sup>2</sup> = 0%) (<a href="./references#CD002001-fig-0023" title="">Analysis 6.2</a>). </p> </section> <section id="CD002001-sec-0075"> <h4 class="title">Incidence of major bleeding during the additional period of follow‐up after cessation of active treatment </h4> <p>No major bleeding occurred during the additional nine months of follow‐up (<a href="./references#CD002001-fig-0026" title="">Analysis 7.2</a>; <a href="./references#CD002001-fig-0029" title="">Analysis 8.2</a>). </p> <p>Analysis of pooled data in nine category I and category II trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>) for the total 12 months of follow‐up showed major bleeding complications in 36 of 1056 participants (3.4%) in the VKA arm versus 20 of 1056 participants (1.9%) in the LMWH group. This difference was in favour of LMWH therapy (Peto OR 0.56, 95% CI 0.33 to 0.95; P = 0.03; 2112 participants; nine studies). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0032" title="">Analysis 9.2</a>). </p> <p>The 12‐month period of follow‐up (combining three months active treatment and nine months follow‐up) in four category I trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) included a total of 25 of 606 participants (4.1%) in the VKA group versus 18 of 605 participants (3.0%) in the LMWH group who had a major bleeding incident, and showed no clear differences between treatment modalities (Peto OR 0.72, 95% CI 0.39 to 1.32; P = 0.28; 1211 participants; four studies). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0035" title="">Analysis 10.2</a>). </p> </section> <section id="CD002001-sec-0076"> <h4 class="title">Mortality during active treatment</h4> <p>All 16 trials reported mortality during allocated treatment with no clear differences between treatment groups. Fifty‐nine of 1702 participants (3.5%) in the VKA treatment group died versus 62 of 1597 participants (3.9%) in the LMWH group, which produced a pooled Peto OR of 1.08 (95% CI 0.75 to 1.56; P = 0.68; 3299 participants; 16 studies; moderate‐quality evidence). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0009" title="">Analysis 1.3</a>; <a href="#CD002001-fig-0006">Figure 6</a>). We obtained similar results when pooling only category I trial data (Peto OR 0.92, 95% CI 0.61 to 1.41; P = 0.71; 1872 participants; seven studies). Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0018" title="">Analysis 4.3</a>). </p> <div class="figure" id="CD002001-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials), outcome; 2.3 mortality." data-id="CD002001-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials), outcome; 2.3 mortality. </p> </div> </div> </div> <p>For two category I trials providing the same initial treatment for both groups (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) and five category I trials providing different initial treatments for the two groups (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>), pooled analyses did not show a clear difference in mortality between treatment modalities (Peto OR 0.89, 95% CI 0.29 to 2.68; P = 0.83; 292 participants; two studies; I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0021" title="">Analysis 5.3</a>); and Peto OR 0.93, 95% CI 0.59 to 1.46; P = 0.76; 1580 participants; five studies; I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0024" title="">Analysis 6.3</a>)). </p> <p>For the 12 trials that considered participants with DVT and for the three trials that considered participants with PE, analysis revealed no clear differences in mortality between treatment modalities (Peto OR 1.10, 95% CI 0.75 to 1.60; P = 0.64; 3021 participants; 12 studies; I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0012" title="">Analysis 2.3</a>); and Peto OR 5.39, 95% CI 0.51 to 57.36; P = 0.16; 202 participants; three studies; I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0015" title="">Analysis 3.3</a>)). </p> </section> <section id="CD002001-sec-0077"> <h4 class="title">Mortality during the additional period of follow‐up after cessation of active treatment</h4> <p>Five category I and five category II trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0005" title="HamannH . Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis [Rezidivprophylaxe nach Phlebothrombose ‐ orale Antikoagulation oder niedermolekulares Heparin subkutan]. VASOMED1998;10:133‐6. HamannH . Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin [Sekundarprophylaxe nach tiefer venenthrombose. Niedermolekulares Heparin versus Cumarin]. Zentralblatt fur Chirurgie1999;124(1):24‐6. ">Hamann 1998</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>) reported an extended follow‐up period for an additional six to nine months and found that 72 of 1296 participants (5.6%) in the VKA arm versus 72 of 1296 participants (5.6%) in the LMWH group (Peto OR 1.00, 95% CI 0.71 to 1.40; P = 1.00; 2592 participants; 10 studies) died. Heterogeneity was assessed as I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0027" title="">Analysis 7.3</a>). We obtained similar results when considering only category I trials (Peto OR 1.06, 95% CI 0.72 to 1.55; P = 0.77; 1691 participants; five studies; I<sup>2</sup> = 0%) (<a href="./references#CD002001-fig-0030" title="">Analysis 8.3</a>). </p> <p>Analysis of mortality for the total 12‐month follow‐up period did not detect a clear difference between treatment modalities for the 10 category I and category II trials (Peto OR 1.09, 95% CI 0.84 to 1.43; P = 0.51; 2592 participants; 10 studies; I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0033" title="">Analysis 9.3</a>)) nor for the five category I trials (Peto OR 1.05, 95% CI 0.78 to 1.42; P = 0.76; 1691 participants; five studies; I<sup>2</sup> = 0% (<a href="./references#CD002001-fig-0036" title="">Analysis 10.3</a>)). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002001-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002001-sec-0078"></div> <section id="CD002001-sec-0079"> <h3 class="title" id="CD002001-sec-0079">Summary of main results</h3> <p>This review detected no clear differences between low‐molecular‐weight heparin (LMWH) and vitamin K antagonists (VKAs) for two of the three primary outcomes (recurrent symptomatic venous thromboembolism (VTE) and overall mortality). For the third outcome, major bleeding, data show a reduction in favour of LMWH (Peto odds ratio (OR) 0.51, 95% confidence interval (CI) 0.32 to 0.80; P = 0.004). However, pooling of data from category I trials alone (clearly concealed randomisation, double‐blind or blinded outcome assessment) revealed no clear differences in major bleeding between treatment groups (Peto OR 0.62, 95% CI 0.36 to 1.07; P = 0.08). Although this review found no evidence that LMWH has greater efficacy than VKAs for long term treatment of VTE, evidence shows that long term treatment of symptomatic VTE with LMWH versus long term treatment with VKAs may be safer with respect to major bleeding. The largest trial (<a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>) reported no clear differences for any of the three outcomes. Results were similar for recurrent symptomatic VTE, major bleeding, and mortality during an additional six to nine months after cessation of the allocated three months of treatment for symptomatic VTE. </p> <p>In interpreting the findings of this review, one must consider several points. Five category I trials did not use the same initial treatment in both treatment arms, and these differences may threaten the validity of data derived from these trials (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>). A previous report suggests that the inferior quality of initial unfractionated heparin treatment may be associated with higher recurrence of VTE during follow‐up (<a href="./references#CD002001-bbs2-0039" title="HullRD , RaskobGE , BrantRF , PineoGF , ValentineKA . The importance of initial heparin treatment on long‐term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Archives of Internal Medicine1997;157(20):2317‐21. ">Hull 1997</a>), and two trials included in the review did not report the quality of unfractionated heparin treatment (<a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>). In the largest trial (<a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>), initial treatment with unfractionated heparin was adequate but produced no differences in effect between treatment modalities. Doses of the various LMWH compounds used in individual trials ranged from 100 IU/kg reviparin sodium to 175 anti‐Xa IU/kg tinzaparin and 4000 anti‐Xa IU enoxaparin. <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a> and Hull (<a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0007" title="HullRD , PineoGF , BrantR , LiangJ , CookR , SolymossS , et al. LITE Trial Investigators. Home therapy of venous thrombosis with long‐term LMWH versus usual care: patient satisfaction and post‐thrombotic syndrome. American Journal of Medicine2009;122(8):762‐9.e3. HullRD , PineoGF , BrantRF , ValentineKA . A randomised trial comparing the effects of long‐term low‐molecular weight heparin (LMWH) with LMWH plus warfarin on the quality of life and safety in the home treatment of proximal deep vein thrombosis (DVT): the home‐LITE study. Thrombosis and Haemostasis1997;77 Suppl(June):Abstract No PS‐1991. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . Home‐LITE: safety and efficacy results for a study investigating the long‐term out‐of hospital treatment of patients with proximal venous thrombosis using subcutaneous low‐molecular‐weight heparin versus warfarin. Thrombosis and Haemostasis2001;86(1):Abstract OC1647. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2009</a>) used the same dose of LMWH for both initial and long term treatment of symptomatic VTE. <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a> recruited only children and adjusted the dose accordingly. These five category I trials found no clear difference in the incidence of recurrent VTE between LMWH and VKAs (Peto OR 0.68, 95% CI 0.44 to 1.03; P = 0.07). </p> <p>In contrast, the two category I trials that provided the same initial treatment for both treatment arms observed a trend in favour of VKAs for prevention of recurrent symptomatic VTE when using relatively low doses of LMWH during long term treatment of deep vein thrombosis (DVT) (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>); dosages were approximately twice those normally used for prophylaxis of symptomatic VTE and were not adjusted for weight. The relatively low dose used is reflected in the very low levels of anti‐Xa activity found after 22 hours (0.04 U/mL after injection of 4000 anti‐Xa IU enoxaparin) (<a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>). </p> <p><a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a> included 25 participants (14 participants in the LMWH treatment group and 11 in the VKA treatment group; n = 158) with infrapopliteal DVT (calf vein thrombosis) diagnosed by duplex ultrasonography. Excluding these data from the sensitivity analysis did not affect findings. Two considerations are of interest here. First, duplex ultrasonography is not as sensitive and specific for distal thrombosis as it is for proximal DVT (<a href="./references#CD002001-bbs2-0050" title="MitchellDC , GrastyMS , StebbingsWS , NocklerIB , LewarsMD , LevisonRA , et al. Comparison of duplex ultrasonography and venography in the diagnosis of deep venous thrombosis. British Journal of Surgery1991;78(5):611‐3. ">Mitchell 1991</a>). Second, the natural history of distal DVT is unclear. It is estimated, from trials of diagnosis, that approximately only 20% of calf vein thrombi develop into a proximal DVT within two weeks of presentation, whereas the remainder, which probably are small and self‐limiting, do not (<a href="./references#CD002001-bbs2-0029" title="HeijboerH , BullerHR , LensingAW , TurpieAG , CollyLP , tenCateJW . A comparison of real‐time compression ultrasonography with impedance plethysmography for the diagnosis of deep‐vein thrombosis in symptomatic outpatients. The New England Journal of Medicine1993;329(19):1365‐9. ">Heijboer 1993</a>; <a href="./references#CD002001-bbs2-0033" title="HuismanMV , BullerHR , tenCateJW , VreekenJ . Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. New England Journal of Medicine1986;314(13):823‐8. ">Huisman 1986</a>; <a href="./references#CD002001-bbs2-0034" title="HuismanMV , BullerHR , tenCateJW , HeijermansHS , van derLaanJ , vanMaanenDJ . Management of clinically suspected acute venous thrombosis in outpatients with serial impedance plethysmography in a community hospital setting. Archives of Internal Medicine1989;149(3):511‐3. ">Huisman 1989</a>; <a href="./references#CD002001-bbs2-0038" title="HullRD , HirshJ , CarterCJ , JayRM , OckelfordPA , BullerHR , et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep‐vein thrombosis. A randomized trial. Annals of Internal Medicine1985;102(1):21‐8. ">Hull 1985</a>). </p> <p>The difference in major bleeding complications favouring LMWH during allocated treatment of three months has to be considered with caution. Different LMWH compounds and relatively low doses of medication were used, as has been mentioned. Although a difference in bleeding incidence favouring LMWH was found when all trials were combined (Peto OR 0.51, 95% CI 0.32 to 0.80; P = 0.004), no clear difference between LMWH and VKA was observed (Peto OR 0.62, 95% CI 0.36 to 1.07; P = 0.08) when only category I trials were considered. These trials used higher dosages of LMWH. On the other hand, the only trial that found a difference in favour of LMWH treatment used the same dose of LMWH for initial treatment as for long term treatment of symptomatic DVT (Peto OR 0.12, 95% CI 0.02 to 0.89) (<a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>). <i>Post hoc</i> analyses showed no clear differences between LMWH and VKA when subsets of fatal and intracranial haemorrhage were assessed. </p> <p>Overall, the data show no substantial differences in efficacy for long term treatment of patients with DVT with LMWH or VKAs, but long term treatment with LMWH may cause fewer episodes of major bleeding than occur with VKA therapy. </p> <p>Currently, many patients are treated at home with a course of subcutaneous LMWH administered by the patients themselves. After this initial treatment, patients continue with a three‐month course of VKA with the dose adjusted to achieve an international normalised ratio (INR) between 2.0 and 3.0. Treatments used in <a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a> and <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a> do not represent current practice. </p> <p>Important practical considerations involving mainly patient and local preferences also influence the choice between LMWH and VKAs. The major disadvantage of VKA treatment compared with LMWH treatment is the need for regular laboratory monitoring. Furthermore, VKA compounds have some major drug interactions, but drug interactions of LMWH are uncommon. In addition, treatment with LMWH is relatively safe during pregnancy (<a href="./references#CD002001-bbs2-0057" title="SansonBJ , LensingAW , PrinsMH , GinsbergJS , BarkaganZS , Lavenne‐PardongeE , et al. Safety of low‐molecular‐weight heparin in pregnancy: a systematic review. Thrombosis and Haemostasis1999;81(5):668‐72. ">Sanson 1999</a>). A major disadvantage of treatment with LMWH is that the patient has to self‐administer subcutaneous injections on a daily basis. Among the included trials, only a few participants stopped treatment with LMWH, mainly as the result of problems other than administration of subcutaneous injections. <a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a> reported that 8% of patients refused to participate in the trial because of reluctance to administer subcutaneous injections by themselves. </p> </section> <section id="CD002001-sec-0080"> <h3 class="title" id="CD002001-sec-0080">Overall completeness and applicability of evidence</h3> <p>Participants with symptomatic VTE included in these trials constituted a representative mix of people with this disease. All trials included approximately similar participants; therefore, these data can be generalised to the wider population. Several published trials included only participants with a diagnosis of cancer who had symptomatic VTE. We did not include these trials in our review because participants do not represent the normal cohort of patients with a diagnosis of symptomatic VTE, and because this is the topic of another Cochrane review (<a href="./references#CD002001-bbs2-0021" title="AklEA , KahaleLA , BarbaM , NeumannI , LabediN , TerrenatoI , et al. Anticoagulation for the long‐term treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD006650.pub4] ">Akl 2014</a>). </p> <p>Only scant data have been gathered on patients with symptomatic pulmonary embolisation (PE). This review includes data from only 202 people with PE, and review findings should be interpreted with caution. </p> <p>Direct oral anticoagulants (DOACs) are changing the ways that patients are treated (<a href="./references#CD002001-bbs2-0055" title="RobertsonL , KestevenP , McCaslinJE . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD010956.pub2] ">Robertson 2015</a>; <a href="./references#CD002001-bbs2-0056" title="RobertsonL , KestevenP , McCaslinJE . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews2015, Issue 12. [DOI: 10.1002/14651858.CD010957.pub2] ">Robertson 2015b</a>). Therefore, in the future, as more and more patients are prescribed DOACs instead of VKA and LMWH, the analysis performed for this review may become outdated. We will reconsider the focus and future of this review in future updates. </p> </section> <section id="CD002001-sec-0081"> <h3 class="title" id="CD002001-sec-0081">Quality of the evidence</h3> <p>Fifty‐nine per cent of included patients (1872/3299) participated in trials with category I classification yielding evidence of highest quality on direct treatment comparisons. </p> <p>All randomised controlled trials included in this systematic review were conducted in an unblinded manner because the two different interventions were delivered in different settings (hospital and home), making participant blinding impossible. When participant outcomes were assessed by individuals who were blind to treatment allocation, we considered threats to the validity of trial conclusions to be reduced. When it was not reported that those collecting outcome measures data were unaware of treatment allocation, trial findings may have been compromised. Trials in which allocation is not concealed and outcomes are not collected in a blind manner are essentially observational rather than experimental in nature. Analysis for only category I trials (clearly concealed randomisation, double‐blind or blinded outcome assessment) shows similar results to those of analyses for all studies combined, except for bleeding, which showed no clear differences between treatment groups. </p> <p>We downgraded the quality of evidence for recurrent VTE and mortality to moderate owing to imprecision resulting from the small number of events and the relatively large confidence interval. We decided not to downgrade for risk of bias due to blinding because a sensitivity analysis excluding studies deemed of low methodological quality confirmed no clear differences between LMWH and VKA. </p> <p>We downgraded the quality of evidence for major bleeding to low owing to risk of bias and inconsistency: a sensitivity analysis including only category I trials (clearly concealed randomisation, double‐blind or blinded outcome assessment) showed no clear differences between VKA and LMWH. Bleeding outcomes are more susceptible to biased outcome reporting than outcomes such as VTE and mortality, and only two studies (studies of low methodological quality) have reported less bleeding with LMWH; the remainder showed no clear differences because confidence intervals crossed the line of no effect. See <a href="./full#CD002001-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD002001-sec-0082"> <h3 class="title" id="CD002001-sec-0082">Potential biases in the review process</h3> <p>Methods used to conduct this review are described in detail in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002001-bbs2-0032" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>); particular strengths include independent application of review eligibility criteria, independent data extraction and assessment of risk of bias, and assessment of quality of evidence according to GRADE. The Cochrane Vascular Information Specialist, who is highly skilled in identification of randomised controlled trials, devised and conducted the search strategies. We are confident that we have included all relevant studies. However, the possibility remains that some relevant trials, particularly in the 'grey' literature (e.g. conference proceedings), have been missed. Other potential biases in the review process are the missing information from three trials regarding aspects of their conduct (<a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0015" title="RomeraA , CairolsMA , Vila‐CollR , MartiX , ColomeE , BonellA , et al. A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis. European Journal of Vascular and Endovascular Surgery2009;37(3):349‐56. Romera‐VillegasA , CairolsMA , Marti‐MestreX , Riera‐BatallaS , Martinez‐RicoC . Effect of the anticoagulant therapy in the thrombus regression: a prospective duplex ultrasound study. Phlebology/Eleventh Meeting of the European Venous Forum:Antwerp, Belgium, 24–26 June 2010. 2010; Vol. 25:302‐3. ">Romera 2009</a>). </p> </section> <section id="CD002001-sec-0083"> <h3 class="title" id="CD002001-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>Three published systematic reviews have previously evaluated VKAs versus LMWH (<a href="./references#CD002001-bbs2-0024" title="BochenekT , NizankowskiR . The treatment of venous thromboembolism with low‐molecular‐weight heparins. A meta‐analysis. Thrombosis and Haemostasis2012;107(4):699‐716. ">Bochenek 2012</a>; <a href="./references#CD002001-bbs2-0028" title="FerrettiG , BriaE , GiannarelliD , CarliniP , FeliciA , MandalaM , et al. Is recurrent venous thromboembolism after therapy reduced by low‐molecular‐weight heparin compared with oral anticoagulants?. Chest2006;130(6):1808‐16. ">Ferretti 2006</a>; <a href="./references#CD002001-bbs2-0043" title="IorioA , GuerciniF , PiniM . Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomised comparisons with oral anticoagulants. Journal of Thrombosis and Haemostasis2003;1(9):1906‐13. ">Iorio 2003</a>). Two reviews did not find a clear difference between LMWH and oral anticoagulants (<a href="./references#CD002001-bbs2-0028" title="FerrettiG , BriaE , GiannarelliD , CarliniP , FeliciA , MandalaM , et al. Is recurrent venous thromboembolism after therapy reduced by low‐molecular‐weight heparin compared with oral anticoagulants?. Chest2006;130(6):1808‐16. ">Ferretti 2006</a>; <a href="./references#CD002001-bbs2-0043" title="IorioA , GuerciniF , PiniM . Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomised comparisons with oral anticoagulants. Journal of Thrombosis and Haemostasis2003;1(9):1906‐13. ">Iorio 2003</a>). </p> <p><a href="./references#CD002001-bbs2-0043" title="IorioA , GuerciniF , PiniM . Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomised comparisons with oral anticoagulants. Journal of Thrombosis and Haemostasis2003;1(9):1906‐13. ">Iorio 2003</a> reviewed the efficacy and safety of long term treatment of VTE with LMWH compared with oral anticoagulants and did not find a clear difference between treatment types in terms of assessment of recurrent VTE (odds ratio (OR) 0.66, 95% CI 0.41 to 1.07), major bleeding (OR 0.45, 95% CI 0.18 to 1.11), or total mortality (OR 1.19, 95% CI 0.78 to 1.83). This meta‐analysis included six trials (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>) and one abstract (<a href="./references#CD002001-bbs2-0040" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. ">Hull 2000</a>). We included all trials in our review except <a href="./references#CD002001-bbs2-0040" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. ">Hull 2000</a>, which is a duplicate report (conference abstract) of the included trial <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>. </p> <p><a href="./references#CD002001-bbs2-0028" title="FerrettiG , BriaE , GiannarelliD , CarliniP , FeliciA , MandalaM , et al. Is recurrent venous thromboembolism after therapy reduced by low‐molecular‐weight heparin compared with oral anticoagulants?. Chest2006;130(6):1808‐16. ">Ferretti 2006</a> reviewed only recurrent VTE after treatment with LMWH compared with oral anticoagulants for people with VTE and found no clear differences between treatments when assessing recurrent symptomatic VTE (OR 1.29, 95% CI 0.82 to 2.02). This meta‐analysis included three trials of patients with cancer, which we excluded for the purpose of this Cochrane review, three other trials that we judged to be of high methodological quality (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>), four that we considered of lower methodological quality (<a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>), and an abstract (<a href="./references#CD002001-bbs2-0041" title="HullRD , PineoGF , MahAF , et al. for the LITE Study Investigators. A randomized trial evaluating long‐term low‐molecular‐weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract]. Blood2002;100:148a. ">Hull 2002</a>) of the included trial <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>. </p> <p>The third systematic review did detect a difference between treatments. <a href="./references#CD002001-bbs2-0024" title="BochenekT , NizankowskiR . The treatment of venous thromboembolism with low‐molecular‐weight heparins. A meta‐analysis. Thrombosis and Haemostasis2012;107(4):699‐716. ">Bochenek 2012</a> reviewed the efficacy and safety of long term treatment of VTE with LMWH compared with oral anticoagulants and found a reduction in episodes of VTE (OR 0.75, 95% CI 0.59 to 0.97) and in the outcome major bleeding (OR 0.59, 95% CI 0.47 to 0.74). This review did not evaluate mortality as an outcome. The <a href="./references#CD002001-bbs2-0024" title="BochenekT , NizankowskiR . The treatment of venous thromboembolism with low‐molecular‐weight heparins. A meta‐analysis. Thrombosis and Haemostasis2012;107(4):699‐716. ">Bochenek 2012</a> review included six trials that we judged to be of high methodological quality (<a href="./references#CD002001-bbs2-0002" title="DasSK , CohenAT , EdmondsonRA , MelissariE , KakkarVV . Low‐molecular‐weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World Journal of Surgery1996;20(5):521‐7. KakkarVV . Dalteparin prevention of recurrent DVT ‐ a study vs. warfarin. Haemostasis1994;24 Suppl 1:45. ">Das 1996</a>; <a href="./references#CD002001-bbs2-0003" title="DaskalopoulosM , DaskalopoulosS , SfiridisP , NicolaouA , DimitroulisD , LiapisC . Long‐term treatment of deep venous thrombosis with low molecular weight heparin: a prospective randomized trial. European Society for Vascular Surgery, Programme and Abstract Book, XVII Annual Meeting and Course on Vascular Surgical Techniques2003:73. DaskalopoulosME , DaskalopoulouSS , TzortzisE , SfiridisP , NikolaouA , DimitroulisD , et al. Long‐term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery2005;29(6):638‐50. ">Daskalopoulos 2005</a>; <a href="./references#CD002001-bbs2-0004" title="Gonzalez‐FajardoJA , ArrebaE , CastrodezaJ , PerezJL , FernandezL , AgundezI , et al. Venographic comparison of subcutaneous low‐molecular‐weight heparin with oral anticoagulant therapy in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery1999;30(2):283‐92. ">Gonzalez 1999</a>; <a href="./references#CD002001-bbs2-0006" title="HullRD , PineoGF , BrantRF . A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long‐term treatment of proximal vein thrombosis. Intensivmedizin und Notfallmedizin2000;37 Suppl 1:123‐32. HullRD , PineoGF , BrantRF , MahAF , BurkeN , DearR , et al. for the LITE Trial Investigators. Self‐managed long‐term low‐molecular‐weight heparin therapy: the balance of benefits and harms. The American Journal of Medicine2007;120(1):72‐82. HullRD , PineoGF , MahAF . Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post‐treatment period for patients randomised to long‐term low‐molecular‐weight heparin (LMWH) versus warfarin sodium. Blood2002;100(11):Abstract 1951. HullRD , PineoGF , MahAF , BrantRF . A randomized trial evaluating long‐term low‐molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1(July):Abstract number: OC395. PineoGF , HullRD , MahAF , LITE Investigators. Does rebound exist? A comparison of venous thromboembolitic event rates in the post‐treatment period for patients randomized to long‐term low‐molecular‐weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis2003;1 Suppl 1:Abstract 1882. ">Hull 2007</a>; <a href="./references#CD002001-bbs2-0012" title="MassicotteP , JulianJ , GentM , ShieldsK , MarzinottoV , SzechtmanB , et al. REVIVE Study Goup. An open‐label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thrombosis Research2003;109(2):85‐92. ">Massicotte 2003</a>; <a href="./references#CD002001-bbs2-0014" title="PiniM , AielloS , ManottiC , PattaciniC , QuintavallaR , PoliT , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):191‐7. ">Pini 1994</a>) and six trials that we judged to be of lower methodological quality (<a href="./references#CD002001-bbs2-0001" title="BeckmanJA , DunnK , SasaharaAA , GoldhaberSZ . Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thrombosis and Haemostasis2003;89(6):953‐8. ">Beckman 2003</a>; <a href="./references#CD002001-bbs2-0008" title="KakkarV , GebskaM , KadziolaZ , RoachC , SabaN , ManningA . Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thrombosis and Haemostasis2001;86 Suppl:Abstract OC 967. KakkarVV , GebskaM , KadziolaZ , SabaN , CarrascoP , Bemiparin Investigators. Low‐molecular‐weight heparin in the acute and longterm treatment of deep vein thrombosis. Thrombosis and Haemostasis2003;89(4):674‐80. ">Kakkar 2003</a>; <a href="./references#CD002001-bbs2-0009" title="KucherN , QuirozR , McKeanS , SasaharaAA , GoldhaberSZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vascular Medicine2005;10(4):251‐6. ">Kucher 2005</a>; <a href="./references#CD002001-bbs2-0010" title="LopaciukS , Bielska‐FaldaH , NoszczykW , BielawiecM , WitkiewiczW , FilipeckiS , et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis1999;81(1):26‐31. ">Lopaciuk 1999</a>; <a href="./references#CD002001-bbs2-0011" title="Lopez‐BeretP , OrgazA , FontcubertaJ , DoblasM , MartinezA , LozanoG , et al. Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis. Journal of Vascular Surgery2001;33(1):77‐90. ">Lopez 2001</a>; <a href="./references#CD002001-bbs2-0016" title="VeigaF , EscribaA , MaluendaMP , Lopez RubioM , MargaletI , LezanaA , et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long‐term treatment of deep venous thrombosis in the elderly: a randomized trial. Thrombosis and Haemostasis2000;84(4):559‐64. ">Veiga 2000</a>). The meta‐analysis by <a href="./references#CD002001-bbs2-0024" title="BochenekT , NizankowskiR . The treatment of venous thromboembolism with low‐molecular‐weight heparins. A meta‐analysis. Thrombosis and Haemostasis2012;107(4):699‐716. ">Bochenek 2012</a> included two trials that considered only patients with cancer, who were excluded for the purpose of this Cochrane review. One of these studies showed a significant effect of LMWH heavily influencing the overall outcome and contributing approximately one‐third of the overall weight; this was likely the reason for the difference between <a href="./references#CD002001-bbs2-0024" title="BochenekT , NizankowskiR . The treatment of venous thromboembolism with low‐molecular‐weight heparins. A meta‐analysis. Thrombosis and Haemostasis2012;107(4):699‐716. ">Bochenek 2012</a> and the current Cochrane review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002001-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002001-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD002001-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD002001-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.1 incidence of recurrent VTE." data-id="CD002001-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.1 incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.2 incidence of major bleeding." data-id="CD002001-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials); outcome: 2.2 incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials), outcome; 2.3 mortality." data-id="CD002001-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment (category I and II trials), outcome; 2.3 mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 3 Mortality." data-id="CD002001-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE, Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 3 Mortality." data-id="CD002001-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT, Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 3 Mortality." data-id="CD002001-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE, Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 3 Mortality." data-id="CD002001-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE, Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 3 Mortality." data-id="CD002001-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH), Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 3 Mortality." data-id="CD002001-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH), Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 3 Mortality." data-id="CD002001-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 LMWH versus VKA during additional follow‐up (category I and II trials), Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 3 Mortality." data-id="CD002001-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 LMWH versus VKA during additional nine months of follow‐up (category I trials), Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 3 Mortality." data-id="CD002001-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials), Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE." data-id="CD002001-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 1 Incidence of recurrent VTE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding." data-id="CD002001-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 2 Incidence of major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002001-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/urn:x-wiley:14651858:media:CD002001:CD002001-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_t/tCD002001-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 3 Mortality." data-id="CD002001-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 LMWH versus VKA for total period of 12 months of follow‐up (category I trials), Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/media/CDSR/CD002001/image_n/nCD002001-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002001-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LMWH compared with VKA for long term treatment of symptomatic VTE</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>LMWH compared with VKA for long term treatment of symptomatic VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE<br/> <b>Setting:</b> hospital and outpatient<br/> <b>Intervention:</b> LMWH<br/> <b>Comparison:</b> VKA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with VKA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of recurrent VTE</b> </p> <p>(treatment duration 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 0.83<br/> (0.60 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3299<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/> (31 to 58) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Incidence of major bleeding</b> </p> <p>(treatment duration 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 0.51<br/> (0.32 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3299<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (10 to 24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(treatment duration 3 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 1.08<br/> (0.75 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3299<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000<br/> (26 to 53) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* The basis for the <b>assumed risk</b> with VKA for 'Study population' was the average risk in the VKA group (i.e. total number of participants with events divided by total number of participants in the VKA group included in the meta‐analysis). <b>The risk in the LMWH group</b> (and its 95% confidence interval) is based on assumed risk in the VKA group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> <br/> CI: confidence interval; LMWH: low‐molecular‐weight heparin; OR: odds ratio; VKA: vitamin K antagonist; VTE: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>High risk of bias due to no blinding but not downgraded, as analysis excluding studies deemed of low methodological quality confirms no clear differences between LMWH and VKA<br/> <sup>b</sup>Downgraded by one level owing to imprecision, small number of events, and relatively large confidence interval<br/> <sup>c</sup>Downgraded by one level for risk of bias, as sensitivity analysis based on category I trials (clearly concealed randomisation, double‐blind or blinded outcome assessment) shows no clear differences between VKA and LMWH. Bleeding outcomes are more susceptible to biased outcome reporting than outcomes such as VTE and mortality<br/> <sup>d</sup>Downgraded by one level for inconsistency: only two studies (studies of low methodological quality) reported less bleeding for LMWH, and the remainder showed no clear differences, with confidence intervals crossing the line of no effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LMWH compared with VKA for long term treatment of symptomatic VTE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/full#CD002001-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.60, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.32, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.75, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.33, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.75, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [0.91, 35.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.03, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.39 [0.51, 57.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I trials) in participants with VTE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.54, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.36, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.61, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LMWH versus VKA during allocated treatment (category I trials) in participants with VTE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.74, 5.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.20, 5.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.29, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.33, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.59, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">LMWH versus VKA during additional follow‐up (category I and II trials)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.77, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.71, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">LMWH versus VKA during additional follow‐up (category I and II trials)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">LMWH versus VKA during additional nine months of follow‐up (category I trials)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.81, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.72, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">LMWH versus VKA during additional nine months of follow‐up (category I trials)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.33, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.84, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">LMWH versus VKA for total period of 12 months of follow‐up (category I and II trials)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002001-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">LMWH versus VKA for total period of 12 months of follow‐up (category I trials)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.39, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.78, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">LMWH versus VKA for total period of 12 months of follow‐up (category I trials)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002001.pub3/references#CD002001-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002001.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002001-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002001-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002001-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD002001-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD002001-note-0001">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002001\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002001\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002001\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002001\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002001\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002001.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002001.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002001.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002001.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002001.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715329610"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002001.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715329615"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002001.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d84736c1ff446',t:'MTc0MDcxNTMzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 